



## Commercial & Healthcare Exchange PA Criteria *Effective: December 20<sup>th</sup>, 2019*

**Prior Authorization:** Brukinsa

**Products Affected:** Brukinsa (zanubrutinib) oral capsule

**Medication Description:** Zanubrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy. Zanutrutinib is a second generation Bruton tyrosine kinase (BTK) inhibitor. BTK is a signaling molecule early within the B-cell antigen receptor (BCR) signaling cascade. Signaling from BCR regulates several pro-survival mechanisms of B-cells, including proliferation, trafficking, chemotaxis, and adhesion. Zanutrutinib forms a covalent bond with a cysteine residue in the BTK active site leading to inhibition of BTK enzymatic activity, inhibition of malignant B-cell proliferation, and reduced tumor growth.

**Covered Uses:** Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy

**Exclusion Criteria:** N/A

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried/failed

**Age Restrictions:** 18 years of age and older

**Prescriber Restrictions:** Prescribed by, or in consultation with, an oncologist

**Coverage Duration:** 12 Months

**Other Criteria:**

- A. Patient has a diagnosis of Mantle Cell Lymphoma; AND
- B. Patient must have received at least one prior therapy for mantle cell lymphoma

**References:**

1. Product Information: BRUKINSA(TM) oral capsules, zanubrutinib oral capsules. BeiGene USA Inc (per FDA), San Mateo, CA, 2019.



## Policy Revision history

<b>Rev #</b>	<b>Type of Change</b>	<b>Summary of Change</b>	<b>Sections Affected</b>	<b>Date</b>
1	New Policy	New Policy	All	12.5.19

